Advertisement
MRK vs PFE
Which Stock Would AI Choose? Merck & Co., Inc. (MRK) vs. Pfizer Inc. (PFE) Stock Comparison
Key Takeaways
- Momentum gap: MRK has staged a meaningful recovery in recent months, while PFE has largely traded flat and continues to underperform the broader market.
- Growth catalysts: Merck's newer launches (Winrevair, Capvaxive, Ohtuvayre) are ramping quickly, whereas Pfizer is still working to offset fading COVID-19 product revenue.
- Patent-cliff positioning: Both companies face upcoming loss of exclusivity on key drugs, but MRK's pipeline and lifecycle strategy are currently viewed more favorably by analysts.
- Tickeron AI Verdict: Based on trend consistency, catalysts, and relative market positioning, the AI currently favors MRK over PFE in this head-to-head comparison.
- For deeper detail, explore MRK Major News and MRK Today's Price Move, as well as PFE Major News and PFE Today's Price Move.
- Interested in automated market analysis? Explore Trending AI Robots to see which strategies are currently resonating with market conditions.
Introduction
Merck & Co., Inc. (MRK) and Pfizer Inc. (PFE) are two of the largest U.S.-based pharmaceutical companies, and both are navigating the same overarching industry themes: patent expirations on blockbuster drugs, pricing and regulatory pressure, and the need to replenish pipelines through research and strategic mergers and acquisitions (M&A). Yet their recent stock behavior has diverged sharply. This comparison is relevant for investors and traders evaluating relative performance within the healthcare sector, and for those weighing momentum and growth catalysts against valuation and dividend income.
MRK Overview and Recent Performance
Merck & Co., Inc. (MRK) is a global pharmaceutical company centered on oncology, vaccines, and a sizable animal-health business. Its immuno-oncology drug Keytruda remains the dominant revenue driver, while newer products such as Winrevair (for pulmonary arterial hypertension) and Capvaxive (a pneumococcal vaccine) have ramped up quickly since launch. In recent months, MRK shares have climbed notably, supported by a series of analyst upgrades and rising price targets from firms including Goldman Sachs, Wells Fargo, and Scotiabank. Sentiment has been bolstered by strategic acquisitions—including Verona Pharma and Cidara Therapeutics—and by progress on a subcutaneous formulation of Keytruda that may extend its commercial runway. A sustained decline in Gardasil vaccine sales, driven largely by weaker demand in China, remains the primary offsetting headwind, along with the looming 2028 loss of exclusivity on Keytruda.
PFE Overview and Recent Performance
Pfizer Inc. (PFE) is a diversified biopharmaceutical company spanning primary care, specialty care, and oncology. Following its pandemic-era sales surge, the company has contended with sharply declining revenue from its COVID-19 products, Comirnaty and Paxlovid. Recent quarters have produced earnings beats and raised guidance, yet the stock has remained largely range-bound as investors weigh ongoing challenges. Growth is increasingly coming from oncology assets such as Padcev and Lobrena, while Eliquis and the Vyndaqel family contribute steady demand. Pfizer has also moved into the obesity market through its acquisition of Metsera. However, near-term patent cliffs on several top drugs, cautious analyst positioning, and a lack of imminent re-rating catalysts have kept market sentiment subdued despite a relatively high dividend yield.
Trending AI Robots
Tickeron operates hundreds of AI Trading Bots that collectively trade thousands of different tickers. Because market conditions shift constantly, only a curated subset of these strategies earns a place in the Trending AI Robots section. These bots vary widely in trading style, strategy, timeframe, performance statistics, and the sets of tickers they follow, allowing users to match an approach to their own objectives and risk tolerance. For example, bots may specialize in swing trading, intraday patterns, or longer-horizon trend following, each with its own track record and risk profile. Browsing the curated list offers a practical way to observe which automated strategies are currently aligned with prevailing market dynamics. Explore the Trending AI Robots page to review the available strategies.
Head-to-Head Comparison
The two companies differ most clearly in market momentum and growth visibility. MRK is demonstrating improving trend consistency, with multiple new product launches beginning to offset softness in vaccines and providing a credible bridge toward its Keytruda patent cliff. PFE, by contrast, trades at a lower valuation and offers a notably higher dividend yield, but its recovery remains more dependent on pipeline execution and on managing the post-COVID revenue decline. In terms of risk, both face patent expirations and pricing-policy pressure; however, MRK's concentrated reliance on Keytruda is a structural risk, while PFE faces a broader set of near-term expirations across its portfolio. On market sentiment, recent analyst activity has trended more favorably for MRK, whereas PFE's consensus rating has remained closer to neutral.
Tickeron AI Verdict
Based on observable factors—including trend consistency, the strength and visibility of near-term catalysts, relative market positioning, and the direction of recent analyst sentiment—Tickeron's AI would currently lean toward MRK as the more favorable setup in this comparison. The stock's improving momentum, successful new product launches, and constructive analyst revisions suggest a relatively stronger risk-reward profile at present. This probabilistic view could shift as new data emerge, particularly around pipeline readouts, patent-cliff execution, and sector-wide pricing developments.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MRK is a Hold and PFE is a Hold.
MRK sees its Stochastic Oscillator recovers from oversold territory
On October 30, 2026, the Stochastic Oscillator for MRK moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 52 instances where the indicator left the oversold zone. In 34 of the 52 cases the stock moved higher in the following days. This puts the odds of a move higher at over 65%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for MRK just turned positive on October 30, 2026. Looking at past instances where MRK's MACD turned positive, the stock continued to rise in 25 of 50 cases over the following month. The odds of a continued upward trend are 50%.
MRK moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for MRK crossed bullishly above the 50-day moving average on November 09, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 50%.
Following a +6.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where MRK advanced for three days, in 191 of 338 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.
The Aroon Indicator entered an Uptrend today. In 172 of 265 cases where MRK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 65%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MRK as a result. In 45 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 54%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 51%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 12 (best 1 - 100 worst), indicating outstanding price growth. MRK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 28 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 58, placing this stock better than average.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 79 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.633) is normal, around the industry mean (-1.421). MRK's P/E Ratio (116.452) is considerably higher than the industry average of (21.700). Projected Growth (PEG Ratio) (2.716) is also within normal values, averaging (5.738). Dividend Yield (0.023) settles around the average of (0.038) among similar stocks. P/S Ratio (5.402) is also within normal values, averaging (4.033).
PFE's Stochastic Oscillator is remaining in oversold zone for 1 day
Be on the lookout for a price bounce soon.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +0.75% 3-day Advance, the price is estimated to grow further. Considering data from situations where PFE advanced for three days, in 153 of 282 cases, the price rose further within the following month. The odds of a continued upward trend are 54%.
The Aroon Indicator entered an Uptrend today. In 86 of 190 cases where PFE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 45%.
Bearish Trend Analysis
The 10-day RSI Indicator for PFE moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In 11 of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at 44%.
The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PFE as a result. In 47 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 53%.
The Moving Average Convergence Divergence Histogram (MACD) for PFE turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 24 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 56%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PFE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 4 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 29 (best 1 - 100 worst), indicating outstanding price growth. PFE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 83 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.966) is normal, around the industry mean (-1.421). P/E Ratio (38.169) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (13.137) is also within normal values, averaging (5.738). Dividend Yield (0.059) settles around the average of (0.038) among similar stocks. P/S Ratio (2.469) is also within normal values, averaging (4.033).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PFE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 58, placing this stock worse than average.
MRK | PFE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 67 | 90 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 88 Overvalued | 96 Overvalued | |
PROFIT vs RISK RATING 1..100 | 28 | 100 | |
SMR RATING 1..100 | 79 | 83 | |
PRICE GROWTH RATING 1..100 | 12 | 29 | |
P/E GROWTH RATING 1..100 | 1 | 4 | |
SEASONALITY SCORE 1..100 | 50 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MRK's Valuation (88) in the Pharmaceuticals Major industry is in the same range as PFE (96). This means that MRK’s stock grew similarly to PFE’s over the last 12 months.
MRK's Profit vs Risk Rating (28) in the Pharmaceuticals Major industry is significantly better than the same rating for PFE (100). This means that MRK’s stock grew significantly faster than PFE’s over the last 12 months.
MRK's SMR Rating (79) in the Pharmaceuticals Major industry is in the same range as PFE (83). This means that MRK’s stock grew similarly to PFE’s over the last 12 months.
MRK's Price Growth Rating (12) in the Pharmaceuticals Major industry is in the same range as PFE (29). This means that MRK’s stock grew similarly to PFE’s over the last 12 months.
MRK's P/E Growth Rating (1) in the Pharmaceuticals Major industry is in the same range as PFE (4). This means that MRK’s stock grew similarly to PFE’s over the last 12 months.
| MRK | PFE | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 44% |
| Stochastic ODDS (%) | 1 day ago 65% | 1 day ago 57% |
| Momentum ODDS (%) | 1 day ago 54% | 1 day ago 53% |
| MACD ODDS (%) | 1 day ago 50% | 1 day ago 56% |
| TrendWeek ODDS (%) | 1 day ago 58% | 1 day ago 55% |
| TrendMonth ODDS (%) | 1 day ago 57% | 1 day ago 48% |
| Advances ODDS (%) | 16 days ago 57% | 4 days ago 54% |
| Declines ODDS (%) | 3 days ago 51% | 6 days ago 56% |
| BollingerBands ODDS (%) | N/A | N/A |
| Aroon ODDS (%) | 1 day ago 65% | 1 day ago 45% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MRK’s FA Score shows that 3 FA rating(s) are green while PFE’s FA Score has 2 green FA rating(s).
- MRK’s FA Score: 3 green, 2 red.
- PFE’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MRK’s TA Score shows that 6 TA indicator(s) are bullish while PFE’s TA Score has 3 bullish TA indicator(s).
- MRK’s TA Score: 6 bullish, 2 bearish.
- PFE’s TA Score: 3 bullish, 4 bearish.
Price Growth
MRK (@Pharmaceuticals: Major) experienced а +0.70% price change this week, while PFE (@Pharmaceuticals: Major) price change was -1.70% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.36%. For the same industry, the average monthly price growth was +2.44%, and the average quarterly price growth was +6.83%.
Reported Earning Dates
MRK is expected to report earnings on Feb 02, 2027.
PFE is expected to report earnings on Feb 02, 2027.
Industries' Descriptions
@Pharmaceuticals: Major (+1.36% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
PFE and
Correlation & Price change
A.I.dvisor indicates that over the last year, PFE has been loosely correlated with BMY. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if PFE jumps, then BMY could also see price increases.
| Ticker / NAME | Correlation To PFE | 1D Price Change % | ||
|---|---|---|---|---|
| PFE | 100% | +0.21% | ||
| BMY - PFE | 60% Loosely correlated | +1.78% | ||
| AMGN - PFE | 53% Loosely correlated | -0.30% | ||
| GSK - PFE | 51% Loosely correlated | +0.51% | ||
| NVS - PFE | 50% Loosely correlated | +0.16% | ||
| BIIB - PFE | 46% Loosely correlated | +1.17% | ||
More | ||||